Transgenic expression of survivin compensates for OX40-deficiency in driving Th2 development and allergic inflammation

European Journal of Immunology

Volumn 43, Issue 7, 2013, Pages 1914-1924

  Lei, Fengyang ^a   Song, Jianyong ^b   Haque, Rizwanul ^a   Xiong, Xiaofang ^a   Fang, Deyu ^c   Wu, Yuzhang ^b   Lens, Susanne M A ^d   Croft, Michael ^e   Song, Jianxun ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Costimulation; Lung inflammation; Murine model; Survivin; Th2 cells

Indexed keywords

CD134 ANTIGEN; INTERLEUKIN 4; INTERLEUKIN 5; SURVIVIN;

ALLERGIC AIRWAY INFLAMMATION; ALLERGIC REACTION; ANIMAL CELL; ARTICLE; CELL HYPERPLASIA; CELL MATURATION; CONTROLLED STUDY; EOSINOPHIL; IN VIVO STUDY; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TH2 CELL; TRANSGENIC MOUSE;

COSTIMULATION; LUNG INFLAMMATION; MURINE MODEL; SURVIVIN; TH2 CELLS;

ANIMALS; CELL DIFFERENTIATION; HYPERSENSITIVITY; INHIBITOR OF APOPTOSIS PROTEINS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PNEUMONIA; RECEPTORS, OX40; REPRESSOR PROTEINS; TH2 CELLS;

EID: 84880007347     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201243081     Document Type: Article

References (31)

1. Song, J., So, T., Cheng, M., Tang, X. and Croft, M., Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity 2005. 22: 621-631.
2. Shinomiya, N., Koike, Y., Koyama, H., Takayama, E., Habu, Y., Fukasawa, M., Tanuma, S. et al., Analysis of the susceptibility of CD57 T cells to CD3-mediated apoptosis. Clin. Exp. Immunol. 2005. 139: 268-278.
3. Uren, A. G., Wong, L., Pakusch, M., Fowler, K. J., Burrows, F. J., Vaux, D. L. and Choo, K. H., Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr. Biol. 2000. 10: 1319-1328.
4. Grossman, D., Kim, P. J., Blanc-Brude, O. P., Brash, D. E., Tognin, S., Marchisio, P. C. and Altieri, D. C., Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J. Clin. Invest. 2001. 108: 991-999.
5. Hoffman, W. H., Biade, S., Zilfou, J. T., Chen, J. and Murphy, M., Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem. 2002. 277: 3247-3257.
6. Okada, H., Bakal, C., Shahinian, A., Elia, A., Wakeham, A., Suh, W. K., Duncan, G. S. et al., Survivin loss in thymocytes triggers p53-mediated growth arrest and p53-independent cell death. J. Exp. Med. 2004. 199: 399-410.
7. Xing, Z., Conway, E. M., Kang, C. and Winoto, A., Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J. Exp. Med. 2004. 199: 69-80.
8. Song, J., Salek-Ardakani, S., So, T. and Croft, M., The kinases aurora B and mTOR regulate the G1-S cell cycle progression of T lymphocytes. Nat. Immunol. 2007. 8: 64-73.
9. Zhao, B., Song, A., Haque, R., Lei, F., Weiler, L., Xiong, X., Wu, Y. et al., Cooperation between molecular targets of costimulation in promoting T cell persistence and tumor regression. J. Immunol. 2009. 182: 6744-6752.
10. Croft, M., Control of immunity by the TNFR-related molecule OX40 (CD134). Annu. Rev. Immunol. 2010. 28: 57-78.
11. Vincenti, F. and Luggen, M., T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation. Annu. Rev. Med. 2007. 58: 347-358.
12. Shankar, M., Nixon, J. C., Maier, S., Workman, J., Farris, A. D. and Webb, C. F., Anti-nuclear antibody production and autoimmunity in transgenic mice that overexpress the transcription factor Bright. J. Immunol. 2007. 178: 2996-3006.
13. Duan, W., So, T. and Croft, M., Antagonism of airway tolerance by endotoxin/lipopolysaccharide through promoting OX40L and suppressing antigen-specific Foxp3+ T regulatory cells. J. Immunol. 2008. 181: 8650-8659.
14. Seshasayee, D., Lee, W. P., Zhou, M., Shu, J., Suto, E., Zhang, J., Diehl, L. et al., In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. J. Clin. Invest. 2007. 117: 3868-3878.
15. Damayanti, T., Kikuchi, T., Zaini, J., Daito, H., Kanehira, M., Kohu, K., Ishii, N. et al., Serial OX40 engagement on CD4+ T cells and natural killer T cells causes allergic airway inflammation. Am. J. Respir. Crit. Care Med. 2010. 181: 688-698.
16. Jember, A. G., Zuberi, R., Liu, F. T. and Croft, M., Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40. J. Exp. Med. 2001. 193: 387-392.
17. Salek-Ardakani, S., Song, J., Halteman, B. S., Jember, A. G., Akiba, H., Yagita, H. and Croft, M., OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J. Exp. Med. 2003. 198: 315-324.
18. Kozmik, Z., Wang, S., Dorfler, P., Adams, B. and Busslinger, M., The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol. Cell Biol. 1992. 12: 2662-2672.
19. Wang, J., Yang, L., Yang, J., Kuropatwinski, K., Wang, W., Liu, X. Q., Hauser, J. et al., Transforming growth factor beta induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells. Cancer Res. 2008. 68: 3152-3160.
20. Zhou, L. J., Smith, H. M., Waldschmidt, T. J., Schwarting, R., Daley, J. and Tedder, T. F., Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B-lymphocyte development. Mol. Cell Biol. 1994. 14: 3884-3894.
21. Maas, A., Dingjan, G. M., Grosveld, F. and Hendriks, R. W., Early arrest in B cell development in transgenic mice that express the E41K Bruton's tyrosine kinase mutant under the control of the CD19 promoter region. J. Immunol. 1999. 162: 6526-6533.
22. Nixon, J. C., Ferrell, S., Miner, C., Oldham, A. L., Hochgeschwender, U. and Webb, C. F., Transgenic mice expressing dominant-negative bright exhibit defects in B1 B cells. J. Immunol. 2008. 181: 6913-6922.
23. Arens, R., Tesselaar, K., Baars, P. A., van Schijndel, G. M., Hendriks, J., Pals, S. T., Krimpenfort, P. et al., Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion. Immunity 2001. 15: 801-812.
24. Gisler, R., Jacobsen, S. E. and Sigvardsson, M., Cloning of human early B-cell factor and identification of target genes suggest a conserved role in B-cell development in man and mouse. Blood 2000. 96: 1457-1464.
25. Kleindienst, P., Chretien, I., Winkler, T. and Brocker, T., Functional comparison of thymic B cells and dendritic cells in vivo. Blood 2000. 95: 2610-2616.
26. Rahman, K. M., Banerjee, S., Ali, S., Ahmad, A., Wang, Z., Kong, D. and Sakr, W. A., 3, 3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Cancer Res. 2009. 69: 4468-4475.
27. Altieri, D. C., Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer 2008. 8: 61-70.
28. Song, J., So, T. and Croft, M., Activation of NF-kappaB1 by OX40 contributes to antigen-driven T cell expansion and survival. J. Immunol. 2008. 180: 7240-7248.
29. Faideau, B., Briand, J. P., Lotton, C., Tardivel, I., Halbout, P., Jami, J., Elliott, J. F. et al., Expression of preproinsulin-2 gene shapes the immune response to preproinsulin in normal mice. J. Immunol. 2004. 172: 25-33.
30. Fathman, J. W., Gurish, M. F., Hemmers, S., Bonham, K., Friend, D. S., Grusby, M. J., Glimcher, L. H. et al., NIP45 controls the magnitude of the type 2 T helper cell response. Proc. Natl. Acad. Sci. USA 2010. 107: 3663-3668.
31. Badovinac, V. P., Messingham, K. A., Jabbari, A., Haring, J. S. and Harty, J. T., Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nat. Med. 2005. 11: 748-756.